← Back to screener

SUPERNUS PHARMACEUTICALS, INC. SUPN

Rank #1744 · Nasdaq · $2.4B market cap
Audited by KPMG LLP, no going-concern flag in the latest filing.
Score
43.0
P/E
1848.8
P/B
2.75
ROE
0.1%
Op. Margin
-0.9%
Debt Ratio
38%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Average

P/E 1848.8x, P/B 2.75x. Ranks in the top 56% of the universe.

Profitability ★★☆☆☆
Weak

ROE 0.1%. Ranks in the top 70% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 38%. Ranks in the top 20% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 8.9% year over year. Ranks in the top 82% of the universe.

Safety is the relative strength · Growth is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2012–$-0.0B$-0.0B$-0.0B–-719
2013$0.0B$-0.0B$0.1B$-0.0B-4701.4-82
2014$0.0B$-0.0B$-0.0B$0.0B-2849.3821
2015$0.0B$-0.1B$-0.1B$0.1B-515.2115
2016$0.1B$-0.0B$-0.0B$0.0B-5.7301
2017$0.1B$0.0B$0.0B$0.0B14.1289
2018$0.2B$0.1B$0.1B$0.1B25.2178
2019$0.3B$0.1B$0.1B$0.2B32.9274
2020$0.4B$0.1B$0.1B$0.3B35.3211
2021$0.4B$0.1B$0.1B$0.5B37.8168
2022$0.5B$0.2B$0.1B$0.6B33.4147
2024$0.7B$0.0B$0.1B$0.8B6.944
2025$0.6B$-0.0B$0.0B$0.9B-0.938

← See the full screener